Xin Lang Cai Jing·2025-06-24 03:14Group 1 - The China Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) has seen a strong increase of 2.30%, with notable gains from stocks such as Kangnola-B (02162) up 6.18% and Ascentage Pharma-B (06855) up 6.09% [1] - The Hong Kong Pharmaceutical ETF (159718) has risen by 1.69%, with a net asset value increase of 56.91% over the past year [1] - In the past month, significant licensing deals have been reported from Chinese innovative pharmaceutical companies, including a $60 billion deal from 3SBio and a $53.3 billion strategic collaboration between CSPC Pharmaceutical and AstraZeneca [1] Group 2 - Dongwu Securities highlights that the current surge in innovative pharmaceuticals is driven by three factors: outbound business development (BD) of innovative drugs, profitability turnaround of companies like BeiGene and Innovent, and an improved domestic innovation environment [2] - In 2024, the volume of innovative drug BD transactions is expected to grow by 6%, with a total transaction value increase of 26%, and upfront payments reaching $4.1 billion, a 16% increase year-on-year [2] - The total value of outbound innovative drug BD is projected to reach $51.9 billion in 2024, with 8-10% as upfront payments, which are recognized as revenue and contribute to net profit [2] Group 3 - The China Medical and Medical Device Innovation Index (931484) has increased by 0.72%, with significant gains from stocks such as Sinocelltech (688520) up 8.60% and Aier Eye Hospital (300015) up 1.59% [4] - The Medical Innovation ETF (516820) has reached a scale of 1.442 billion yuan, with consistent net inflows over the past five days totaling 52.81 million yuan [4] - The top ten weighted stocks in the China Medical and Medical Device Innovation Index account for 66.57% of the index, including major players like Hengrui Medicine (600276) and WuXi AppTec (603259) [10] Group 4 - The top ten weighted stocks in the China Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index account for 60.77%, with companies like BeiGene (06160) and WuXi Biologics (02269) leading the index [7] - The performance of the top stocks in the Hong Kong Pharmaceutical ETF shows a range of increases, with WuXi Biologics at 2.45% and BeiGene at 2.97% [9] - The Medical Innovation ETF's top holdings include WuXi AppTec (603259) and Hengrui Medicine (600276), with respective weights of 11.68% and 10.22% [12]